Literature DB >> 29766549

Leukocytoclastic vasculitis associated with immunoglobulin A lambda monoclonal gammopathy of undetermined significance: A case report and review of previously reported cases.

Hiroshi Umemura1,2, Osamu Yamasaki1, Keiji Iwatsuki1.   

Abstract

Leukocytoclastic vasculitis is often associated with immunoglobulin (Ig)A deposition on the vascular walls. IgA-associated leukocytoclastic vasculitis comprises various underlying diseases. Hematological disorders that can be minor triggers include multiple myeloma and monoclonal gammopathy of undetermined significance. Here, we present the case of a 78-year-old woman with leukocytoclastic vasculitis associated with monoclonal gammopathy of undetermined significance of the IgA lambda chain. Oral steroid administration initially showed remission of vasculitis; however, the condition recurred after four attempts of treatment withdrawal. We also reviewed previous reports of 14 cases of IgA-associated leukocytoclastic vasculitis, of which 11 were associated with multiple myeloma and three with monoclonal gammopathy of undetermined significance.
© 2018 Japanese Dermatological Association.

Entities:  

Keywords:  M-protein gammopathy; immunoglobulin A-associated vasculitis; leukocytoclastic vasculitis; monoclonal gammopathy of undetermined significance; myeloma

Mesh:

Substances:

Year:  2018        PMID: 29766549     DOI: 10.1111/1346-8138.14466

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  1 in total

1.  IgA vasculitis with underlying monoclonal IgA gammopathy: innovative therapeutic approach targeting plasma cells. A case series.

Authors:  Antoine Hankard; Saskia Ingen-Housz-Oro; Khalil El Karoui; Romain Paule; Bertrand Lioger; Benoit Brihaye; Maxime Battistella; Stéphanie Jobard; Julie Magnant; Elisabeth Diot; Adrien Bigot; Nicole Ferreira-Maldent; Sophie Deriaz; Ann-Rose Cook; Hélène Henique; Francois Maillot; Achille Aouba; Alexandra Audemard-Verger
Journal:  Clin Rheumatol       Date:  2022-06-17       Impact factor: 3.650

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.